Literature DB >> 12490602

Attenuation of amiodarone-induced pulmonary fibrosis by vitamin E is associated with suppression of transforming growth factor-beta1 gene expression but not prevention of mitochondrial dysfunction.

Jeffrey W Card1, William J Racz, James F Brien, Thomas E Massey.   

Abstract

Amiodarone (AM) is an efficacious antidysrhythmic agent that can cause numerous adverse effects, including potentially life-threatening pulmonary fibrosis. The current study was undertaken to investigate potential protective mechanisms of vitamin E against AM-induced pulmonary toxicity (AIPT) in the hamster. Three weeks after intratracheal administration of AM (1.83 micromol), increased pulmonary hydroxyproline content and histological damage were observed, indicative of fibrosis. These effects were preceded by increased pulmonary levels of transforming growth factor (TGF)-beta1 mRNA at 1 week post-AM, which remained elevated 3 weeks post-AM. Dietary supplementation with vitamin E resulted in rapid pulmonary accumulation of the vitamin, and prevention of AM-induced increases in TGF-beta1, hydroxyproline, and histological damage. Although dietary supplementation also markedly elevated lung mitochondrial vitamin E content, it did not attenuate AM-induced inhibition of mitochondrial respiration or disruption of mitochondrial membrane potential in vitro, or lung mitochondrial respiratory inhibition resulting from in vivo AM administration. These results suggest that vitamin E reduces the extent of pulmonary damage after AM administration via down-regulating TGF-beta1 overexpression but that it does not modify AM-induced mitochondrial dysfunction, a potential initiating event in AIPT.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12490602     DOI: 10.1124/jpet.102.043208

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  9 in total

Review 1.  Amiodarone: review of pulmonary effects and toxicity.

Authors:  Spyros A Papiris; Christina Triantafillidou; Likurgos Kolilekas; Despoina Markoulaki; Effrosyni D Manali
Journal:  Drug Saf       Date:  2010-07-01       Impact factor: 5.606

Review 2.  Antioxidants as potential therapeutics for lung fibrosis.

Authors:  Brian J Day
Journal:  Antioxid Redox Signal       Date:  2008-02       Impact factor: 8.401

Review 3.  Amiodarone pulmonary toxicity.

Authors:  N Wolkove; M Baltzan
Journal:  Can Respir J       Date:  2009 Mar-Apr       Impact factor: 2.409

4.  Interaction with the hERG channel and cytotoxicity of amiodarone and amiodarone analogues.

Authors:  K M Waldhauser; K Brecht; S Hebeisen; H R Ha; D Konrad; D Bur; S Krähenbühl
Journal:  Br J Pharmacol       Date:  2008-07-07       Impact factor: 8.739

Review 5.  Statin adverse effects : a review of the literature and evidence for a mitochondrial mechanism.

Authors:  Beatrice A Golomb; Marcella A Evans
Journal:  Am J Cardiovasc Drugs       Date:  2008       Impact factor: 3.571

6.  Ultrastructural Changes in Rat's Atrial Cardiomyocytes After Short Term Administration of Amiodarone and Possible Protective Role of Vitamin E.

Authors:  Abdullah S Shatoor; Mohamed Samir Ahmad Zaki; Refaat A Eid; Mohamed A Sayed-Ahmad
Journal:  J Clin Med Res       Date:  2012-05-15

7.  Effects of N-acetyl cysteine, vitamin E and vitamin C on liver glutathione levels following amiodarone treatment in rats.

Authors:  Esin Akbay; Beril Erdem; Ahmet Ünlü; Ahmet Barış Durukan; Mehmet Ali Onur
Journal:  Kardiochir Torakochirurgia Pol       Date:  2019-06-28

8.  Crucial Role of PLGA Nanoparticles in Mitigating the Amiodarone-Induced Pulmonary Toxicity.

Authors:  Amira Motawea; Dalia Alsaied Moustafa Ahmed; Ahmed A El-Mansy; Noha Mohamed Saleh
Journal:  Int J Nanomedicine       Date:  2021-07-08

9.  May toxicity of amiodarone be prevented by antioxidants? A cell-culture study.

Authors:  Ahmet Baris Durukan; Beril Erdem; Elif Durukan; Handan Sevim; Tugce Karaduman; Hasan Alper Gurbuz; Aylin Gurpinar; Cem Yorgancioglu
Journal:  J Cardiothorac Surg       Date:  2012-06-28       Impact factor: 1.637

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.